YSOPIA -Model Yso2 -Develop Christensenella Gut Bacteria

Yso2 is a preclinical program targeting Crohn’s disease. It aims to develop Christensenella gut bacteria as a safe, efficient and groundbreaking oral biotherapy. YSOPIA has identified a lead candidate to relieve Crohn’s disease associated symptoms and slow down disease progression. Discover the articles we published in Scientific Reports: Relizani et al. 2022 and Kropp et al. 2021. Our team has selected from our proprietary strain library a lead candidate with high anti-inflammatory potential and protective action on gut epithelium.